Commonwealth Equity Services’s Iovance Biotherapeutics IOVA Stock Holding History

Commonwealth Equity Services’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	54,426 +800	+1%	+$3.04K	﹤0.01%	4029
2026 Q1	$188K	Buy	53,626 +2,127	+4%	+$6.8K	﹤0.01%	4024
2025 Q4	$141K	Sell	51,499 -151	-0.3%	-$349	﹤0.01%	4063
2025 Q3	$112K	Sell	51,650 -2,043	-4%	-$4.82K	﹤0.01%	4069
2025 Q2	$92K	Sell	53,693 -1,765	-3%	-$4.39K	﹤0.01%	4077
2025 Q1	$185K	Buy	55,458 +23,944	+76%	+$123K	﹤0.01%	3868
2024 Q4	$233K	Buy	31,514 +16,113	+105%	+$149K	﹤0.01%	3632
2024 Q3	$145K	Buy	15,401 +1,996	+15%	+$18.9K	﹤0.01%	3801
2024 Q2	$108K	Buy	13,405 +3,133	+31%	+$33.6K	﹤0.01%	3796
2024 Q1	$152K	Buy	+10,272	New	+$120K	﹤0.01%	3706
2021 Q4	–	Sell	-9,491	Closed	-$234K	–	3692
2021 Q3	$234K	Sell	9,491 -511	-5%	-$12K	﹤0.01%	3145
2021 Q2	$260K	Buy	10,002 +2,992	+43%	+$77.8K	﹤0.01%	3038
2021 Q1	$221K	Buy	7,010 +1,565	+29%	+$64.9K	﹤0.01%	3054
2020 Q4	$252K	Buy	+5,445	New	+$216K	﹤0.01%	2724

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Commonwealth Equity Services's IOVA Position: Q2 2026 in Review

Commonwealth Equity Services increased its Iovance Biotherapeutics (IOVA) stake by 1.5% in Q2 2026, buying an estimated $3.04K and bringing the position to 54,426 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #4029.

Commonwealth Equity Services first reported a position in IOVA in Q4 2020 and has held it in 14 quarters since. The position peaked at $260K in Q2 2021. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Commonwealth Equity Services held 54,426 shares of Iovance Biotherapeutics worth $226K as of Q2 2026.
Commonwealth Equity Services bought 800 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.04K.
Iovance Biotherapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4029 holding.
Commonwealth Equity Services first reported a position in Iovance Biotherapeutics in Q4 2020 and has held it in 14 quarters since.
Commonwealth Equity Services's Iovance Biotherapeutics position peaked at $260K in Q2 2021.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.